PMID- 10655280
OWN - NLM
STAT- MEDLINE
DCOM- 20000224
LR  - 20061115
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 31
IP  - 2
DP  - 2000 Feb
TI  - Cellular and humoral immune responses induced by intradermal or intramuscular 
      vaccination with the major hepatitis B surface antigen.
PG  - 521-7
AB  - The vaccination route may influence the success of immunization against 
      pathogens. The conventional intramuscular (i.m.) application of a vaccine 
      containing the hepatitis B virus (HBV) surface antigen (HBsAg) led to protective 
      anti-HBs antibody levels in the majority of vaccine recipients. In this study, we 
      vaccinated healthy volunteers and a group of i.m. vaccine nonresponders via the 
      intradermal (i.d.) route and analyzed the HBV-specific B-cell response as well as 
      class-II- and class-I-restricted T-cell responses by (3)H-thymidine uptake, 
      enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunospot assay 
      (ELISPOT). The results were then compared with i.m. vaccinated controls. I.d. 
      vaccinations were well tolerated and induced neutralizing anti-HBs antibodies in 
      all naive vaccine recipients and, importantly, all but one former i.m. 
      nonresponder developed protective anti-HBs serum antibody levels after 2 or 3 
      i.d. immunizations. On the cellular level, i.d. vaccine recipients showed 
      significantly higher anti-HBs producing B-cell frequencies and more vigorous 
      class-II-restricted T-helper (Th) cell responses than i.m. controls. However, 
      although the HBsAg-specific T cells were characterized by their cytokine release 
      as Th1-like cells in both groups, human leukocyte antigen (HLA)-A2+ individuals 
      who received the soluble HBsAg via the i.d. route developed higher 
      peptide-specific cytotoxic CD8+ T cell precursor (CTLp) frequencies. In 
      conclusion, i.d. HBsAg vaccination is more effective even in former i.m. vaccine 
      nonresponders with respect to antibody induction and specific B- and T-cell 
      responses. The induction of virus-specific CTLp may provide the rationale to 
      study the i.d. HBsAg vaccine in the treatment of chronic hepatitis B.
FAU - Rahman, F
AU  - Rahman F
AD  - I. Department of Internal Medicine, Johannes-Gutenberg-University, Mainz, 
      Germany.
FAU - Dahmen, A
AU  - Dahmen A
FAU - Herzog-Hauff, S
AU  - Herzog-Hauff S
FAU - Bocher, W O
AU  - Bocher WO
FAU - Galle, P R
AU  - Galle PR
FAU - Lohr, H F
AU  - Lohr HF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Antibody Formation
MH  - B-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Hepatitis B Antibodies/immunology
MH  - Hepatitis B Surface Antigens/administration & dosage/immunology/*therapeutic use
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - Injections, Intradermal
MH  - Injections, Intramuscular
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - T-Lymphocytes, Helper-Inducer/immunology
MH  - *Vaccination
EDAT- 2000/02/03 09:00
MHDA- 2000/02/26 09:00
CRDT- 2000/02/03 09:00
PHST- 2000/02/03 09:00 [pubmed]
PHST- 2000/02/26 09:00 [medline]
PHST- 2000/02/03 09:00 [entrez]
AID - S0270913900417696 [pii]
AID - 10.1002/hep.510310237 [doi]
PST - ppublish
SO  - Hepatology. 2000 Feb;31(2):521-7. doi: 10.1002/hep.510310237.